GYKI-16084. Treatment of BPH α1/α2-adrenoceptor antagonist

Drugs of the Future

Volumn 24, Issue 10, 1999, Pages 1072-1077

  Mátyus, Péter ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (1,4 BENZODIOXAN 2 YLMETHYLAMINO)PROPYL] 3(2H) PYRIDAZINONE; 2 [3 [(2 BENZO[1,4]DIOXANYL)METHYLAMINO]PROPYL] 3(2H) PYRIDAZINONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; PRAZOSIN; STEROID 5ALPHA REDUCTASE; TERAZOSIN; TESTOSTERONE; UNCLASSIFIED DRUG; YOHIMBINE;

AREA UNDER THE CURVE; BLOOD PRESSURE; DRUG DISTRIBUTION; DRUG SYNTHESIS; HEART RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICTURITION REFLEX; NONHUMAN; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; REVIEW;

EID: 2942753463     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.10.553380     Document Type: Review

References (21)

1. Mátyus, P., Hársing, L., Karimné Tapfer, M. et al. (Gyógyszerkutató Intézet Kft). 3(2H)-Pyridazinone derivs. and pharmaceutical compsns. containing these cpds. WO 9638441.
2. Oesterling, J.E. Benign prostatic hyperplasia. Medicinal and minimally invasive treatment options. New Engl J Med 1995, 332: 99-109.
3. von Brom, S. Benign prostatic hyperplasia. Deutscher Apoth Zeit 1996, 136: 29-36.
4. Kenny, B., Ballard, S., Blagg, J., Fox, D. Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem 1997, 40: 1293-315.
5. Cooper, J.W., Pepho, R.W. Cost-effective management of benign prostatic hyperplasia. Drug Benefit Tr 1995, 7: 10-48.
6. Mátyus, P., Horváth K. α-Adrenergic approach in the medicinal management of benign prostatic hyperplasia. Med Res Rev 1997, 6: 523-35.
7. Lee, M., Sharifi, R. Benign prostatic hyperplasia: Diagnosis and treatment guidelines. Ann Pharmacother 1997, 31: 481-6.
8. 1-Adrenoceptor antagonists as treatment for benign prostatic hyperplasia. Exp Opin Invest Drugs 1995, 4: 915-23.
9. 1-adrenoreceptor antagonists. Urologe A 1997, 36: 18-34.
10. Narayan, P., Tewari, A. Overview of α-blocker therapy for benign prostatic hyperplasia. Urology 1998, 51: 38-45.
11. 1-Adrenoceptor selectivity: Clinical or theoretical benefit? Br J Urol 1995, 76: 57-61.
12. 2-adrenoceptor subtypes: Therapeutic implications. Exp Opin Invest Drug, 1997, 6: 367-87.
13. 1A-adrenergic receptor antagonists. Effects of pharmacophore regie-and stereochemistry on potency and selectivity. Bioorg Med Chem Lett 1998, 8: 2495-500.
14. 1A-adrenergic receptor antagonists. Bioorg Med Chem Lett 1998, 8: 2467-72.
15. 2 receptors in human prostatic urethral tissue. Br J Urol 1993, 72: 68-73.
16. Caine, M. Reflections on α blockade therapy for benign prostatic hyperplasia. Br J Urol 1995, 75: 265-70.
17. Hieble, J.P., McCafferty, G.P., Naselsky, D.P., Bergsma, D.J., Ruffolo, R.R. Recent progress in the pharmacotherapy of diseases of the lower urinary tract. Eur J Med Chem 1995, 30(Suppl.): 269-98S.
18. Mátyus, P., Kosáry, J., Kasztreiner, E. et al. Synthesis, antihypertensive and α-adrenoceptor activity of novel 2-aminoalky-3(2H)-pyridazinones. Eur J Med Chem 1992, 27: 107-14.
19. Kasztreiner, E., Mátyus, P., Rabloczky, G., Jaszlits, L. GYKI-12743. Drugs Fut 1989, 14: 622-4.
20. Mátyus, P., Varga, I., Tapfer, M., Harsing, I., Tomory, E., Simay, A. GYKI-16084: A new drug candidate for treatment of benign prostatic hyperplasia. 15th EFMC Int Symp Med Chem (Sept 6-10, Edinburgh) 1998, Abst P.4.
21. 2-adrenoceptor antagonist tor the treatment of benign prostatic hyperplasia. Eur Urol 1999, 36(Suppl. 1): 116.